(Q37344525)

19 August 2017

0 references

1 reference

title

Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer (English)

1 reference

19 August 2017

0 references

1 reference

1 reference

John P A Ioannidis

0 references

Georgia Salanti

0 references

Davide Mauri

1 reference

19 August 2017

Nikolaos P Polyzos

series ordinal

1 reference

19 August 2017

Nicholas Pavlidis

series ordinal

1 reference

19 August 2017

language of work or name

English

0 references

publication date

9 December 2008

1 reference

Journal of the National Cancer Institute

19 August 2017

published in

1 reference

19 August 2017

volume

100

1 reference

19 August 2017

1 reference

19 August 2017

page(s)

1780-1791

1 reference

Global cancer statistics, 2002

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Estimates of the cancer incidence and mortality in Europe in 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Evaluation of networks of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Simultaneous comparison of multiple treatments: combining direct and indirect evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Indirect comparisons of competing interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Trends in recommendations of myelosuppressive chemotherapy for the treatment of breast cancer: evolution of the national comprehensive cancer network guidelines and the cooperative group studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Exploring the geometry of treatment networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Indirect comparisons: the mesh and mess of clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Response and survival in advanced breast cancer after two non-cross-resistant combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma.A southwest cancer chemotherapy study group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Differential response to chemotherapy in metastatic breast cancer in relation to estrogen receptor level. Results of a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Comparison of mitozantrone and epirubicin in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

A randomized, prospective, comparative, multicentre trial of a single combination versus alternating combinations of antitumour drugs in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Combination chemotherapy of advanced breast cancer. Comparison of dibromodulcitol, doxorubicin, vincristine, and fluoxymesterone to thiotepa, doxorubicin, vinblastine, and fluoxymesterone: an Eastern Cooperative Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized p

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Cancer Study Group and The Southeastern Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Phase II trials of baker's antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5-fluorodeoxyuridine plus arabinosyl cytosine in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Advanced breast cancer: a phase II trial with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN414

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJN414

1 reference

19 August 2017

1 reference